153732-25-3

Basic information

• Product Name: TERT-BUTYL 3-BROMOPHENETHYLCARBAMATE
• Synonyms: TERT-BUTYL 3-BROMOPHENETHYLCARBAMATE
• CAS NO: 153732-25-3
• Molecular Formula: C₁₃H₁₈BrNO₂
• Molecular Weight: 300.2
• Mol File: 153732-25-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: TERT-BUTYL 3-BROMOPHENETHYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-BROMOPHENETHYLCARBAMATE(153732-25-3)
• EPA Substance Registry System: TERT-BUTYL 3-BROMOPHENETHYLCARBAMATE(153732-25-3)

Safety Data

• Hazardous Substances Data: 153732-25-3(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 58971-11-2 2-(3-bromophenyl)ethanamine 
• 42287-90-1 3-(3-bromophenyl)propanoic acid 
• 3132-99-8 m-bromobenzoic aldehyde 
• 14473-91-7 3-bromocinnamic acid 
• 3650-77-9 methyl 3-(3'-bromophenyl)-acrylate 
• 151583-29-8 methyl 3-(3'-bromophenyl)-propionate 
• 31938-07-5 (3-bromophenyl)acetonitrile 

Downstream Products

• 1027261-73-9 {2-[3-(Hydroxy-pyridin-3-yl-methyl)-phenyl]-ethyl}-carbamic acid tert-butyl ester 
• 898271-34-6 tert-butyl [2-(3-cyanophenyl)ethyl]carbamate 
• 214964-28-0 2-amino-4'-(2-tert-butoxycarbonylaminoethyl)-5-chlorobenzophenone 
• 214977-59-0 2-amino-3'-(2-tert-butoxycarbonylaminoethyl)-5-chloro-benzophenone 
• 1370452-93-9 (3-{2-[(tert-butoxycarbonyl)amino]ethyl}phenyl)boronic acid 
• 878158-09-9 trans-methyl 3-(3'-{2''-[3'''-(2''''-tert-butoxycarbonylaminoethyl)phenyl]vinyl}phenyl)-propionate 
• 878158-10-2 (E)-1-(3-(2-aminoethyl)phenyl)-2-(O-methyl hydrocinnam-3’-yl)-ethene 
• 878158-11-3 methyl trans-3-{3-[2-[3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethyl]phenyl]vinyl]phenyl}propionate 
• 878158-12-4 trans-3-{3-[2-[3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethyl]phenyl]vinyl]phenyl}propionic acid 
• 878158-08-8 [2-(3'-vinyl-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 1007575-45-2 4′-({2-[(4,4-dimethylcyclohexyl)amino]ethyl}oxy)-2′-methyl-3-biphenylcarboxamide trifluoroacetate 

Relevant articles and documents

Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior

We have shown that CB1 receptor negative allosteric modulators (NAMs) attenuated the reinstatement of cocaine-seeking behaviors in rats. In an effort to further define the structure-activity relationships and assess the druglike properties of the 3-(4-chlorophenyl)-1-(phenethyl)urea-based CB1 NAMs that we recently reported, we introduced substituents of different electronic properties and sizes to the phenethyl group and evaluated their potency in CB1 calcium mobilization, cAMP, and GTPγS assays. We found that 3-position substitutions such as Cl, F, and Me afforded enhanced CB1 potency, whereas 4-position analogues were generally less potent. The 3-chloro analogue (31, RTICBM-189) showed no activity at >50 protein targets and excellent brain permeation but relatively low metabolic stability in rat liver microsomes. Pharmacokinetic studies in rats confirmed the excellent brain exposure of 31 with a brain/plasma ratio Kp of 2.0. Importantly, intraperitoneal administration of 31 significantly and selectively attenuated the reinstatement of the cocaine-seeking behavior in rats without affecting locomotion.

DUAL KINASE-BROMODOMAIN INHIBITORS

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

DFT-Assisted Design and Evaluation of Bifunctional Amine/Pyridine-Oxazoline Metal Catalysts for Additions of Ketones to Unactivated Alkenes and Alkynes

Bifunctional catalyst systems for the direct addition of ?-ketones to unactivated alkenes/alkynes were designed and modeled by density functional theory (DFT). The designed catalysts possess bidentate ligands suitable for binding of pi-acidic group 10 met

NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors

Neuronal nitric oxide synthase (nNOS) inhibition is a promising strategy to treat neurodegenerative disorders, but the development of nNOS inhibitors is often hindered by poor pharmacokinetics. We previously developed a class of membrane-permeable 2-amino

Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors

Neuronal nitric oxide synthase (nNOS) is a target for development of antineurodegenerative agents. Most nNOS inhibitors mimic l-arginine and have poor bioavailability. 2-Aminoquinolines showed promise as bioavailable nNOS inhibitors but suffered from low

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.